oseltamivir
Tamiflu · ATC code J05AH02
Brand names: Tamiflu, Oseltamivir Hec Pharm, Oseltamivir Stada, Oseltamivir Zentiva, Cyovel, Enfluvir, Enzaflu, Etamivir, Fluzavir, Novavir, Oseflu, Oselmir, Ovireflu, Reliflu, Seltavir
- Key facts
- Active substance
- oseltamivir
- Drug class
- Neuraminidase inhibitor
- ATC code
- J05AH02
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Tamiflu 30 mg hard capsules / Tamiflu 45 mg hard capsules / Tamiflu 75 mg hard capsules · Tamiflu 6 mg/ml powder for oral suspension
- Marketing authorisation holder
- Roche Registration GmbH
- Information as of
- 2026-10-27
Key facts
Oseltamivir is a neuraminidase inhibitor active against influenza viruses (Tamiflu hard capsules and powder for oral suspension). It is used to treat and prevent influenza.
What it is used for
- Treatment of influenza in adults and children including full-term neonates with typical symptoms when influenza is circulating; efficacy shown when started within two days
- Post-exposure prevention in individuals 1 year or older after contact with an influenza case
- In exceptional situations seasonal prevention from 1 year; during a pandemic also post-exposure prevention under 1 year
- Not a substitute for influenza vaccination
Dosing
- Adults and adolescents 13 years and over, treatment: 75 mg twice daily for 5 days (10 days if immunocompromised), started within the first two days
- Post-exposure prevention: 75 mg once daily for 10 days; during a community outbreak up to 6 weeks
- Children 1 year or older: weight-based, e.g. 10 kg to 15 kg 30 mg, > 15 kg to 23 kg 45 mg, > 23 kg to 40 kg 60 mg, > 40 kg 75 mg (treatment twice daily)
- Infants 0 to 12 months (treatment): 3 mg/kg twice daily
- Renal impairment (treatment): creatinine clearance > 30 to 60 ml/min 30 mg twice daily, > 10 to 30 ml/min 30 mg once daily; ≤ 10 ml/min not recommended
Contraindications
- Hypersensitivity to the active substance or any excipient
Important warnings
- Effective only against illness caused by influenza viruses; not a substitute for vaccination
- Susceptibility of circulating strains is highly variable
- Efficacy in immunocompromised patients not firmly established
- Neuropsychiatric events, especially in children and adolescents; monitor closely for behavioural changes
Side effects
- Adults/adolescents: most common nausea and vomiting, mostly once on day 1 or 2
- Children: most common vomiting
- Rare serious: anaphylactic reactions, hepatic disorders, angioneurotic oedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, GI bleeding, neuropsychiatric disorders
Interactions
- Clinically significant interactions via CYP450 are unlikely
- Probenecid causes an approximate 2-fold increase in active metabolite exposure; no adjustment with normal renal function
Pregnancy and breastfeeding
- Pregnancy: large amount of data showing no malformative or feto/neonatal toxicity; may be considered if necessary after weighing benefit and risk
- Breastfeeding: low levels in breast milk; administration may be considered
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- Ebilfumin · genericActavis Group PTC ehf · EMEA/H/C/003717
- TamifluRoche Registration GmbH · EMEA/H/C/000402
Source: European Medicines Agency (EMA), product information
Germany
- Oseltamivir Hec PharmHec Pharm Gmbh · 1 register entry
- Oseltamivir StadaStada Arzneimittel Ag · 1 register entry
- Oseltamivir ZentivaZentiva Pharma Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- CyovelSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
- EnfluvirATABAY KİMYA SAN. VE TİC. A.Ş. · 4 register entries
- EnzafluABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- EtamivirTEBEM İLAÇ SAN. TUR. VE TİC. A.Ş. · 1 register entry
- FluzavirDEVA HOLDİNG A.Ş. · 4 register entries
- NovavirKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 2 register entries
- OsefluNEUTEC İLAÇ SAN. TİC. A.Ş · 6 register entries
- OselmirBİLİM İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
- OvirefluWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- RelifluİLKO İLAÇ SAN.VE TİC. A.Ş. · 1 register entry
- SeltavirALİ RAİF İLAÇ SAN. A.Ş. · 1 register entry
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 14 more European countries
- Bulgaria
- Бетафлу
- Estonia
- Segosana
- France
- Oseltamivir Zentiva
- Hungary
- Segosana
- Iceland
- Ebilfumin, Tamiflu
- Italy
- Viruflu
- Latvia
- Segosana
- Liechtenstein
- Ebilfumin, Tamiflu
- Lithuania
- Segosana
- Netherlands
- Oseltamivir Zentiva, Segosana
- Norway
- Ebilfumin, Tamiflu
- Poland
- Griptavir Med, Oseltamivir Stada, Oseltix, Segosana, Tamivil, Trustar, Viseltam
- Romania
- Oseltamivir Accord, Oseltamivir Laropharm, Segosana, Sinflu
- Spain
- Oseltamivir Accord
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Tamiflu – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC J05AH.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.